Modern Obesity Treatments are changing what is possible in weight management. GLP-1 and next-generation anti-obesity medicines can deliver clinically meaningful weight loss, but they also create new needs across the patient journey.

The gut is central to this new support category. It sits at the intersection of appetite regulation, digestion, nutrient absorption, immune signalling, metabolic health and daily wellbeing.

A 2026 review, “GLP-1 agonists and the gut microbiome: A bidirectional relationship,” describes the gut microbiome as an emerging frontier in GLP-1 and metabolic research. The review highlights that gut microbes and their metabolites may influence GLP-1 secretion and metabolic signalling, while GLP-1 agonists may also reshape microbial composition.

At the same time, the real-world needs around GLP-1 therapy are becoming clearer. A 2025 joint advisory, “Nutritional priorities to support GLP-1 therapy for obesity,” from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society identifies gastrointestinal side effects, reduced calorie intake, risk of nutrient inadequacy, muscle and bone loss, discontinuation and weight regain as key challenges during GLP-1 therapy. The advisory concludes that structured nutrition and lifestyle support before, during and after treatment is central to helping clinicians advance patient health. 

Modern Obesity Treatments can reduce total calorie intake by 16–39%. This is one reason they are effective, but it also changes the gut environment. With less food intake, altered nutrient patterns and common digestive side effects, patients may need better support for gut health, digestive comfort and nutritional resilience. 

This is the scientific and clinical rationale behind Azento Health

We have built azh-biotics® as our microbiome technology foundation – developed by an experienced team with expertise across obesity care, GLP-1s, microbiome science, formulation, clinical development and commercial execution.

Our technology platform is designed to support the real-world needs emerging around Modern Obesity Treatments: gut health, digestive comfort, microbiome resilience, nutrition quality, hydration routines, protein intake, muscle preservation and long-term wellbeing.

Our technology foundation

The azh-biotics® technology platform is based on selected bacterial strains, evidence-informed formulation design, clinical studies, basic research and strain-level traceability.

Research and development

We are investing actively in research to strengthen the scientific foundation of the platform. Azento Health has initiated multiple research projects, including in vitro and in vivo work,  large clinical trials and real-world evidence programs (RWE) with Forte80®. These projects are designed to build deeper understanding of how microbiome-based companion support can fit into the evolving landscape of obesity care and Modern Obesity Treatments.

A pipeline across the full patient journey

Obesity treatment is not one single moment. It is a journey. Patients may need support before treatment starts, during dose escalation, through active weight loss, during long-term treatment, and after treatment interruption or discontinuation.

That is why Azento Health is building a pipeline of 10+ products and concepts across the full patient journey – both under our own brand and through partner-developed, unbranded solutions.

Our ambition is to become a leading microbiome-based companion platform for modern obesity care.